The earnings call highlighted significant revenue growth across all segments, strong performance of Legend Biotech's CAR-T product, and a robust cash position. However, the Group faced challenges with net losses due to Legend Biotech, temporary impacts on gross margins, and capacity issues in ProBio. Despite these challenges, the positive achievements and growth outweigh the difficulties.

Company Guidance

During the 2025 interim results conference call, GenScript provided detailed guidance on their financial and operational performance for the first half of the year and projections for the second half. The company reported an impressive 82% year-over-year revenue growth, with the adjusted profit from continuing operations significantly increasing to approximately USD 180 million. Key highlights included the GenScript Life Science business achieving an 11.3% revenue increase to USD 248 million, and ProBio exhibiting a robust 511% growth to USD 247 million. Bestzyme also experienced a revenue rise of 8.4% to USD 28.3 million. Legend Biotech's CAR-T product, CARVYKTI, treated over 7,500 patients and saw a 136% increase in net trade sales to USD 439 million. GenScript forecasts continued growth, with GenScript Life Science's full-year revenue expected to increase by 13% to 15% and anticipates ProBio to recognize additional milestone payments in the second half. The company maintains a strong cash position of USD 970 million, supporting global expansion and R&D initiatives. Additionally, GenScript remains committed to advancing ESG initiatives, earning a silver medal from EcoVadis and an AA rating from MSCI ESG, reflecting their dedication to sustainability and governance.

Record Revenue Growth

The Group's revenue increased by 81.9% year-over-year to approximately USD 519 million. All three segments achieved growth, with GenScript Life Science growing by 11.3%, ProBio by 511%, and Bestzyme by 8.4%.

Successful CAR-T Product Performance

Legend Biotech's CARVYKTI, a best-in-class CAR-T product, treated over 7,500 patients, with net trade sales growing 136% to USD 439 million in the second quarter.

Strong Cash Position

The Group's cash position stood at USD 970 million, supporting global expansion, R&D progress, and capacity ramp-up.

ESG Achievements

Significant breakthroughs in global ESG ratings, including a silver medal from EcoVadis, an MSCI ESG rating upgrade to AA, and inclusion in the FTSE4Good Index series.

ProBio's Return to Growth

ProBio achieved a return to revenue growth after two challenging years, driven by platform innovation and quality system enhancement.

Innovation in Life Science

The Life Science segment reported a 52% growth in services revenue, with advancements in TurboCHO high-throughput platform and CRISPR solutions.

Genscript Biotech (HK:1548) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

HK:1548 Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 27, 2026	2025 (Q4)	-0.08 / -	11.546	―	―	―
Aug 17, 2025	2025 (Q2)	0.62 / -0.17	-0.648	73.49% (+0.48)
Mar 12, 2025	2024 (Q4)	-0.08 / 11.55	-0.491	2449.21% (+12.04)
Aug 09, 2024	2024 (Q2)	-0.08 / -0.65	-0.343	-88.64% (-0.30)
Mar 10, 2024	2023 (Q4)	-0.39 / -0.49	-0.351	-40.00% (-0.14)
Aug 20, 2023	2023 (Q2)	- / -0.34	-0.491	30.16% (+0.15)	―	―
Mar 30, 2023	2022 (Q4)	-0.46 / -0.35	-7.482	95.31% (+7.13)	―	―
Aug 31, 2022	2022 (Q2)	- / -0.49	-0.359	-36.96% (-0.13)	―	―
Mar 20, 2022	2021 (Q4)	- / -0.96	-0.37	-159.19% (-0.59)	―	―
Aug 23, 2021	2021 (Q2)	- / -0.36	-0.468	23.33% (+0.11)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

HK:1548 Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Mar 12, 2025	HK$13.50	HK$12.80	-5.19%
Aug 09, 2024	HK$12.96	HK$13.34	+2.93%
Mar 30, 2023	HK$17.98	HK$16.80	-6.56%
Aug 31, 2022	HK$25.20	HK$25.45	+0.99%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Genscript Biotech (HK:1548) report earnings?

Genscript Biotech (HK:1548) is schdueled to report earning on Mar 27, 2026, TBA (Confirmed).

What is Genscript Biotech (HK:1548) earnings time?

Genscript Biotech (HK:1548) earnings time is at Mar 27, 2026, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of Genscript Biotech stock?

The P/E ratio of Genscript Biotech is N/A.

What is HK:1548 EPS forecast?

HK:1548 EPS forecast for the fiscal quarter 2025 (Q4) is -0.08.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing